Bioanalytische Lösungen für Pharma
Bioanalytik von Small Molecules
Pharmakokinetik (PK), Toxikokinetik (TK) und Pharmakodynamik (PD) Studien
Metabolite Profiling, Substanzidentifzierung und Strukturaufklärung
Biomarker Analysen
Haben Sie Fragen zu unseren Services?
Wir beraten und unterstützen Sie gerne bei Ihrem Projekt oder Ihrer Studie. Senden Sie uns Ihre Anfrage und teilen Sie uns Ihre konkreten Wünsche mit.
Unsere Biomarker Methoden
| Biomarker | Exposure to | Matrix | Analytical Technique | Reference |
|---|---|---|---|---|
| 11-dehydro-TXB2 | Inflammation | Urine | LC-MS/MS | |
| 2,3-dinor-8-iso-PGF2α | Oxidative Stress | Urine | LC-MS/MS | |
| 2,3-dinor-TXB2 | Inflammation | Urine | LC-MS/MS | |
| 8-iso-PGF2α | Oxidative Stress | Urine | LC-MS/MS | |
| Leukotriene E4 | Inflammation | Urine | LC-MS/MS | |
| Metabolomics (GC) | — | Urine, Plasma, Saliva, Exhaled Breath | GC-TOF-MS | |
| Metabolomics (LC) | — | Urine, Plasma, Saliva | LC-Orbitrap-MS | |
| PGF2α | Oxidative Stress | Urine | LC-MS/MS | |
| Prostaglandin D | Oxidative Stress | Urine | LC-MS/MS | |
| Prostaglandin E | Oxidative Stress | Urine | LC-MS/MS |
Metabolomic Fingerprinting in Various Body Fluids of a Diet-Controlled Clinical Smoking Cessation Study Using a Validated GC-TOF-MS Metabolomics Platform
Goettel M, Niessner R, Mueller D, Scherer M, Scherer G, Pluym N
Journal of Proteome Research, Volume 16(10), doi: 10.1021/acs.jproteome.7b00128.
Untargeted metabolomic profiling in saliva of smokers and nonsmokers by a validated GC-TOF-MS method
Mueller DC, Piller M, Niessner R, Scherer M, Scherer G
Journal of Proteome Research, Volume 13, doi: 10.1021/pr401099r
Development of a human biomonitoring method for assessing the exposure to ethoxyquin in the general population
Stoeckelhuber M, Scherer M, Bracher F, Peschel O, Leibold E, Scherer G, Pluym N
Archives of Toxicology, volume 94, doi: 10.1007/s00204-020-02871-7
Human metabolism and urinary excretion kinetics of the UV filter Uvinul A plus® after a single oral or dermal dosage
Stoeckelhuber M, Scherer M, Peschel O, Leibold E, Bracher F, Scherer G, Pluym N
International Journal of Hygiene and Environmental Health, 227:113509, doi: 10.1016/j.ijheh.2020.113509
A simple and robust UPLC-SRM/MS method to quantify urinary eicosanoids
Sterz K, Scherer G, Ecker J
Journal of Lipid Research, Volume 53, doi: 10.1194/jlr.D023739
Analysis of Urinary Eicosanoids by LC-MS/MS Reveals Alterations in the Metabolic Profile after Smoking Cessation
Goettel M, Niessner R, Scherer M, Scherer G, Pluym N
Chemical Research in Toxicology, Volume 31, doi: 10.1021/acs.chemrestox
Identifying suitable biomarkers of biological effects (BOBEs) for evaluating reduced risk products
Scherer G, Pluym N, Scherer M
CORESTA Congress 2018, Biomarker Workshop, Kunming, China
Review of biomarkers to assess the effects of switching from cigarettes to modified risk tobacco products
Peck MJ, Sanders EB, Scherer G, Luedicke F, Weitkunat R
Biomarkers, Volume 23(3), doi: 10.1080/1354750X.2017.1419284
Suitability of biomarkers of biological effects (BOBEs) for assessing the likelihood of reducing the tobacco related disease risk by new and innovative tobacco products: A literature review
Scherer G
Regulatory Toxicology and Pharmacology, Volume 94, doi: 10.1016/j.yrtph.2018.02.002
Pioniere in der Biomarker-Forschung
Alle im ABF entwickelten Biomarker-Methoden wurden in Fachzeitschriften mit Peer-Review-Verfahren veröffentlicht. Eine Tatsache, die die Validität, Transparenz und wissenschaftliche Evidenz der Bioanalytik untermauert. Dies ist vor allem für Zulassungsanträge bei Regulatoren von Bedeutung.